By using a methodology based on competitive panning against gp140 in presence of excess of gp120 we identified seven new human monoclonal antibodies, m42-48, which bound to gp140s from primary isolates representing different clades. Some of them also bound a gp41-Fc fusion protein but not peptides and denatured gp140 suggesting that their epitopes are conformational; they competed with the cluster IV antibody T3 suggesting involvement of membrane proximal regions. The antibody Fabs inhibited entry mediated by envelope glycoproteins from primary isolates from different clades with potency on average comparable to that of Fab Z13; one of these antibodies, m48, was much more potent in an IgG1 format. Some of the antibodies were converted to scFvs to test the possibility for steric restriction effects; the experiments are ongoing and the results will be presented. These results indicate the possibility that conformational epitopes on gp41 could be a target for broadly neutralizing antibodies and may have potential for the development of new vaccine immunogens.
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